An abstract titled “Real-World evidence of eflapegrastim (efla) usage in patients with gastrointestinal (GI) malignancies” was published by authors Howard Franklin; Jeffrey Crawford; John H. Baird; Kenneth Crist; Vincent Marino; Neil Shah; Lee S. Schwartzberg. The authors are affiliated with Assertio, Duke University Medical Center, City of Hope National Medical Center, Atropos Health and Renown Health-Pennington Cancer Institute.
Short Summary:
Patients receiving chemotherapy for GI malignancies who were treated with efla were older and had a higher burden of comorbidities than those treated with pegfilgrastim (peg). The incidence of febrile neutropenia (FN) was similar and low between treatments. Other adverse events were also comparable between the two groups. These real-world findings suggest the safety and efficacy of efla in adult patients with GI malignancies receiving diverse chemotherapy regimens.